Phenomenex Inc., a global leader in the research and manufacture of advanced technologies for the separation sciences, introduces Yarra 1.8µm SEC-X150 – a high-resolution gel filtration (GFC)/aqueous size-exclusion (SEC) column for the separation of biomolecules on HPLC and UHPLC systems. The 
proprietary new Yarra surface chemistry, combined with bio-inert column hardware, reduces sample adsorption compared to other GFC/SEC columns currently on the market, providing improved recovery and more accurate quantitation of biomolecules. Yet the new Yarra SEC-X150 is priced below these other sub-2µm GFC/SEC products.
 
With a wide molecular weight range (1 – 450 kDa) and high efficiency, Yarra SEC-X150 columns are well suited for the ultra-high-resolution separation and characterization of proteins and peptides including monoclonal antibodies (mAbs), antibody aggregates, antibody drug conjugates (ADCs), insulin and biosimilars on UHPLC systems. Because Yarra SEC-X150 columns typically operate at backpressures below 3,500 psi, they can deliver improved performance (greater resolution, better peak shape and faster analysis time) for existing 3µm and 5µm GFC/SEC column methods on HPLC systems. Designed and manufactured for stability, reproducibility and long product life, the new 
Yarra SEC-X150 and the existing six Yarra 3µm/5µm phases are all supported by an unmatched product quality and performance guarantee.  
 
“GFC/SEC columns currently available from other suppliers are expensive and have left customers frustrated with tedious, solvent- and sample-wasting column priming protocols,” explained Simon Lomas, strategic marketing manager for Phenomenex. “The new Yarra SEC-X150 utilizes greater inertness to overcome sample adsorption while offering an extended molecular range and increased efficiency for better biomolecule characterization, all at an extremely affordable price point.”
 
Phenomenex is a global technology leader committed to developing novel analytical chemistry solutions that solve the separation and purification challenges of researchers in industrial, clinical research, government and academic laboratories. From drug discovery and pharmaceutical development to food safety and environmental analysis, Phenomenex chromatography solutions accelerate science and help researchers improve global health and well-being.  
 
For more information on Phenomenex, visit www.phenomenex.com or follow the company on Twitter @Phenomenex.